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Introduction: Cachexia is a devastating condition that increases morbidity and 
mortality rates  in cancer patients. It often becomes evident only at advanced disease 
stages, when responsiveness to currently available treatments may be limited or even 
absent. The progressive loss of muscle mass is by far the most prominent feature of 
cancer cachexia, negatively affecting physical function and quality of life. We previously 
reported that reduced IGF-1 expression and enhanced myostatin signaling in the muscle 
of tumor-bearing animals. The present study was aimed at investigating whether similar 
perturbations occur in gastric cancer patients as well.  
Methods: Early perturbations of myostatin and IGF-1 signaling (including the expression 
of muscle-specific ubiquitin-ligases) were investigated in 16 gastric cancer patients and in 
6 control subjects analyzing muscle mRNA expression by both semi-quantitative RT-PCR 
and real-time PCR. 
Results: In gastric cancer patients, muscle mRNA levels for IGF-1, myostatin and atrogin-
1 were reduced while MuRF1 expression was unchanged. Changes occurred irrespective 
of weight loss (≤ 5% or > 5%).  
Discussion: The observation that IGF-1 and myostatin mRNA levels are down-regulated 
in gastric cancer patients with minimal or no weight loss indicates that molecular 
alterations in the skeletal muscle should be regarded as an early event in the course of the 
disease. This is particularly relevant in order to devise preventative and therapeutic 
strategies for cancer cachexia.   
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Introduction 
Patients with neoplastic disease frequently develop cachexia, a multifactorial 
syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat 
mass) and alterations of energy balance, driven by a variable combination of reduced food 
intake and abnormal metabolism.  Conventional nutritional support cannot fully reverse this 
life-threatening pathological condition.1 Some of the causative factors had been identified, 
although the mechanisms underlying muscle protein hypercatabolism, one of the most 
important features of cachexia, still remain elusive. In particular, most of the information 
available about the pathogenesis of cachexia are derived from experimental studies, and 
very little is directly known about human cancer. Moreover, since cachexia often becomes 
clinically evident at a rather advanced disease stage, the detection of early subclinical 
perturbations that may be indicative of a situation of ‘pre-cachexia’2,3 is important in order 
to take appropriate preventive measures to prevent the onset of overt cachexia. 
Studies performed in the last decade led to unravel signaling pathways potentially 
contributing to the onset of muscle wasting. Particularly interesting, in this regard, are 
those regulated by Insulin-like growth factor (IGF)-1 and myostatin. The former is an 
anabolic growth factor known to stimulate protein synthesis rates in the skeletal muscle, as 
well as to induce satellite cells to proliferate and differentiate.4 Inhibition of apoptotic cell 
death and suppression of proteolysis, mainly due to down-regulation of the ubiquitin-
proteasome system are some of the effects exerted by IGF-1 on muscle tissue.5 In this 
regard, reduced IGF-1 circulating levels were reported in catabolic states such as cancer 
and sepsis.6-8  
Myostatin has been proposed to negatively regulate skeletal muscle mass.9 Muscle 
hypertrophy in cattles and humans has been reported to be associated with myostatin 
inactivating mutations.10,11 Consistently, increased muscle mass develops in mice when 
myostatin gene is disrupted, or the levels of active myostatin are low. Similarly, 
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overexpression of a dominant negative form of the myostatin receptor ActRIIB, or 
administration of soluble ActRIIB lead to muscle hypertrophy.12,13 By contrast, high 
myostatin levels result in extensive skeletal muscle depletion.13,14 Myostatin protein levels 
are increased in ageing, denervation atrophy or mechanical unloading,15 while reduced in 
the regenerative response induced in muscles by bupivacaine or notexin.16,17 Results from 
our laboratory demonstrate that myostatin signaling is enhanced in the skeletal muscle of 
tumor-bearing rats and mice 18,19 and consistently, myostatin inhibition by antisense 
oligonucleotides, by administration of an ActRIIB/Fc fusion protein or and ActRIIB soluble 
form prevent muscle wasting in tumor-bearing mice.20-22 
 Aim of the present study was to investigate whether early molecular perturbations 
occur in the skeletal muscle of gastric cancer patients. For this purpose, gene expression 
of myostatin, IGF-1 and muscle-specific ubiquitin ligases atrogin-1 and MuRF1 was 
evaluated. 
 
Material and methods 
Patients 
 Sixteen patients with gastric cancer admitted to the Department of Surgery, Second 
Faculty of Medicine, ‘Sapienza’ University of Rome, Italy, were included.  The study was 
approved by the local ethical committee and written informed consent was obtained from 
all patients before enrolment in the study. Diagnosis of gastric cancer was made by 
endoscopic biopsy. Patients undergoing abdominal surgery for non-neoplastic diseases 
(inguinal hernia, laparocele, abdominal aorta aneurysm) served as controls (n = 6). 
Exclusion criteria for both groups  were: liver failure, diabetes, acute or chronic renal 
failure, metabolic acidosis, AIDS, inflammatory bowel disease, autoimmune disorders, 
sepsis, chronic obstructive pulmonary disease, chronic heart failure, hepatitis, 
hyperthyroidism. Some of the subjects enrolled in the present study also participated in a 
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previous investigation from our group.23 After an overnight fast, subjects were studied at 
8:00 am.  Nutritional assessment was performed by evaluating anthropometric 
parameters, usual body weight, percent weight loss, biochemical and immunological 
indices (see Table 1).  
Muscle biopsy 
A biopsy specimen was obtained from the rectus abdominis muscle during the initial 
phase of the operation. The anterior sheet of the rectus abdominis muscle was opened 
with scissors after skin incision and dissection through the subcutaneous fat, and a muscle 
biopsy specimen weighing about 0.5 g was obtained. The biopsy specimen was 
immediately frozen in liquid nitrogen and then stored at -80°C until analysis. Small 
bleeding vessels were carefully controlled with ligatures and cautery after the muscle 
biopsy had been obtained, whereafter the operation continued in a routine fashion. No 
complications occurred from the biopsy procedure.  
Reverse Transcription-PCR 
Total RNA was extracted using the TriPure reagent (Roche, Indianapolis, IN, USA) 
and following manufacturer’s instructions. RNA concentration was determined 
spectrophotometrically (260nm), purity ensured by 260/280nm ratio, and integrity checked 
by electrophoresis on 1.2% agarose gel, containing morpholino propane-sulfonic acid 
(MOPS) 0.02 M and 18% formaldehyde (37%).  
mRNA levels of the analytes were determined by semiquantitative RT-PCR using 
the kit ‘Ready-to-Go’ (GE Healthcare, Milano, Italy). Primers for GAPDH, IGF-1, Myostatin, 
Atrogin-1 and MuRF1 were obtained according to published sequences (Table 2; 
Invitrogen, Milano, Italy). Retrotranscription was performed at 42°C for 30 min. 
Amplification was run as specified in Table 2. Positive and negative controls were 
performed. PCR products (GAPDH = 497bp; IGF-1 = 184bp; Myostatin = 79bp; Atrogin-1 = 
168bp; MuRF-1 = 225bp) were electrophoresed on 2% agarose gels and visualized by 
 6 
staining with ethidium bromide. A 100bp-standard DNA ladder (Fermentas, Burlington, 
ON, Canada) was used to estimate PCR products length. Quantification was performed by 
densitometric analysis: individual product bands and representative background were 
excised from each gel lane and analyzed by means of a specific software (Phoretix). The 
results were normalized according to GAPDH expression (conditions of amplification 
reported in Table 2). Groups were compared in the linear range of amplification. 
As for real-time PCR, a new RNA extraction was performed as reported above. 
RNA was quantified fluorimetrically using the Quant-iT RiboGreen reagent (Molecular 
Probes, Eugene, OR, USA). 0,5 g of total RNA were retro-transcribed to cDNA using the 
iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Transcript levels were 
determined by using the SsoFast Evagreen Supermix and the MiniOpticon thermal cycler 
(Bio-Rad). 10 seconds of denaturation at 95 °C were followed by 30 seconds of 
annealing/extension at 60 °C and repeated for 40 cycles. Gene expression was 
normalized to both GAPDH and TBP expression (see Table 2 for primer sequences).  
Data analysis and presentation 
Results are expressed as mean ± SEM. Significance of the differences was evaluated 
by Student's unpaired 't' test corrected according to Welch, as well as by a non-parametric 
test (Mann-Whitney), and were considered significant at p<0.05. Data obtained from the 
two tests were comparable.  
 
Results  
 Subject characteristics are shown in Table 1. Mean age was 64  2.75 years for 
patients and 62  5.71 years for controls (data expressed as means ± SEM). Body weight 
loss <5% was detectable in 8 out of the 16 patients (50%), while median weight loss of the 
whole group (n = 16) was 5.45% (see ref. 2). As for clinical parameters, only haemoglobin 
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levels were significantly decreased in cancer patients with respect to control values (Table 
1). Such reduction did not correlate with body weight loss and muscle gene expression. 
IGF-1 mRNA expression in the skeletal muscle of gastric cancer patients was 
markedly reduced (70% of controls; p< 0.05; figure 1A), even more when real-time PCR 
was used (controls = 1 ± 1.693, patients = 0.62 ± 1.46; normalized fold expression, 
p<0.05; figure 1B). The reduction was maintained also when patients were stratified 
according to weight loss (<5%: 72% of controls; >5%: 76% of controls; performed on RT-
PCR data), while IGF-1 expression was comparable in stage I-II or III-IV patients (stage I-
II: 0.34 ± 0.03, n = 12; stage III-IV: 0.36 ± 0.02, n = 4). 
Muscle myostatin  mRNA expression was markedly and significantly (p<0.001) 
reduced with respect to control subjects (figure 2A and 2B), irrespective of body weight 
loss (<5%: 49% of controls; >5%: 47% of controls). Also for myostatin, the reduction 
observed in real-time PCR is more marked (controls = 1 ± 1.79, patients = 0.30 ± 1.18; 
normalized fold expression, p<0.001; figure 2B). No differences were observed when 
patients were stratified according to tumor stage (stage I-II: 0.46 ± 0.04, n = 12; stage III-
IV: 0.37 ± 0.01, n = 4). In addition, no correlation with IGF-1 expression was observed 
(Spearman test: r = 0.336, p = 0.240). 
Gene expression for both atrogin-1 and MuRF1 in gastric patients and controls is 
shown in figure 3. Atrogin-1 expression was 45% of controls (p<0.001). Such observation, 
however, was not confirmed by real-time PCR, that revealed only a tendency to reduction, 
not statistically significant (controls = 1 ± 1.41, patients = 0.74 ± 1.35; normalized fold 
expression, p = 0.817).  As for MuRF1, no significant differences were observed between 
controls and cancer patients, although real-time PCR revealed a tendency to increase that 
did not reach significance (controls = 1 ± 1.23, patients = 1.42 ± 1.27; normalized fold 
expression, p = 0.296). Stratification according to body weight loss lead to comparable 
results for both ubiquitin ligases (atrogin-1: <5% = 49% of controls, >5% = 45% of controls; 
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MuRF1:  <5% = 118% of controls, >5% = 112% of controls). Ubiquitin ligase expression 
was not changed in stage I-II compared with stage III-IV patients (Atrogin-1: stage I-II, 0.41 
± 0.04, n = 12; stage III-IV, 0.51 ± 0.08, n = 4. MuRF1: stage I-II, 0.38 ± 0.01, n = 12; stage 
III-IV, 0.36 ± 0.03, n = 4). 
 
Discussion 
The results obtained in the present study show that, similarly to experimental 
cachexia, IGF-1 mRNA expression is significantly reduced in the skeletal muscle of gastric 
cancer patients.  
This is the first study reporting that IGF-1 mRNA levels are decreased in the muscle 
of cancer patients, supporting the hypothesis that a down-regulation of the IGF-1 signaling 
is involved also in the pathogenesis of human cancer cachexia. Interestingly, such 
reduction is detectable either when patients are pooled together, or when they are 
stratified according to body weight loss (<5% or >5%). This is an important finding since it 
further confirms that observations made in experimental models may well apply to human 
cancer. Moreover, similar observations showing a marked down-regulation of IGF-1 and 
IGF-binding proteins 3, 4 and 5 despite an increase in IGF-1R expression have been 
reported in a study conducted on patients affected by sporadic amyotrophic lateral 
sclerosis24. However, such a view cannot be generalized. Indeed, the expression levels of 
muscle myostatin mRNA, which have been shown to be enhanced in tumor-bearing 
animals, are significantly reduced in gastric cancer patients. This result appears 
particularly surprising as we previously reported an increase in myostatin protein level in  
gastric cancer  patients.23   Although the reason for these apparently contradictory results 
is not known at present, the differences may at least in part be due to  post-transcriptional 
mechanisms such as increased myostatin synthesis secondary to increased translational 
efficiency or reduced degradation of myostatin. Interestingly enough a similar discrepancy 
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between myostatin mRNA and protein levels have been previously reported in other 
conditions associated to muscle atrophy.25,26 It should be noted, however, that most of the 
patients included in the present study were in disease stages 1 or 2. It cannot be excluded 
that myostatin perturbations may become apparent in more advanced stages of the 
disease when more significant weight loss and cachexia occur. Further research in this 
respect is warranted. Finally, reduced myostatin mRNA might reflect an early 
compensatory response activated by the muscle to maintain the homeostasis.  
Previous results from our laboratories showed that hyperactivation of the ATP-
ubiquitin-dependent proteolytic system is an early event in the skeletal muscle of gastric 
cancer patients. Indeed, both ubiquitin mRNA expression and proteasome enzymatic 
activities were found significantly elevated before any evidence of body weight loss.23,27 In 
the present study the expression of muscle-specific ubiquitin ligases atrogin-1 and MuRF1 
was assessed.  As for  IGF-1 and myostatin, also atrogin-1 and MuRF1 expression was 
evaluated by both RT-PCR and real-time PCR. While both techniques gave qualitatively 
comparable results for IGF-1 and myostatin, the data obtained for atrogin-1 and MuRF1 
were slightly different. Indeed, the significant reduction of atrogin-1 mRNA levels when 
evaluated by RT-PCR was no more evident by real-time PCR, although a tendency to 
decrease occurred. Similarly, MuRF1 expression was unchanged in cancer patients with 
respect to controls, whether evaluated by RT-PCR or by real-time PCR, although the latter 
showed a tendency to increase. On the whole, our conclusion is that muscle-specific 
ubiquitin ligase gene expression is not significantly modified in cancer hosts, at least in the 
present group of patients.  Such observations agree with those reported by a previous 
study showing that atrogin-1 and MuRF1 gene expression in gastric cancer patients was 
not significantly affected, despite a trend toward increase occurred.28   
The reasons for these inconsistencies remain so far unknown, underscoring the 
need for further studies aimed at clarifying whether increased mRNA expression for 
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ubiquitin ligases may really be considered a molecular marker of muscle atrophy also in 
human diseases associated with muscle loss. In this regard, muscle atrophy in patients 
affected by spinal cord injury is associated with low expression of IGF-1, MuRF1 and 
atrogin-1.29  However, it cannot be excluded that in human cancer cachexia a significant 
increase in atrogin-1 and MuRF1 mRNA levels may occur with greater rates of weight loss. 
This hypothesis is supported by the observation that reduced expression of proteasome 
subunits was not apparent in cancer patients with weight loss < 10%.30 Indeed gastric 
cancer patients included  in the present study presented only minimal or no weight loss. 
Interestingly,  in the present study, no increase of atrogin-1 mRNA levels could be 
detected, either by RT-PCR or by real-time PCR.  Although this finding is somehow 
surprising, it should be noted that pharmacological correction of muscle wasting in cancer 
cachexia is not always paralleled by changes in atrogin-1 expression.7,31 This observation 
suggests that changes of muscle mass and atrogin-1 mRNA levels might not be tightly 
coupled. This hypothesis is also consistent with another report showing that restoration of 
normal atrogin-1 expression induced in fasted or diabetic rats by IGF-1 treatment was not 
associated with muscle mass recovery.32 In addition, reduced protein degradation rates 
resulting from incubation of muscles isolated from burned rats in the presence of GSK3-β 
inhibitors was reported to occur irrespective of changes in atrogin-1 mRNA levels.33 
Finally, there are no available reports demonstrating a correlation between ubiquitin ligase 
mRNA levels and proteasome enzymatic activity. Based on these observation, Attaix and 
Baracos recently proposed that “atrogin-1 expression is a poor index of muscle 
proteolysis”.34 
In conclusion, although the sample size might represent a limitation, the present 
study shows for the first time that both IGF-1 and myostatin mRNA expression are reduced 
in the skeletal muscle of gastric cancer patients and suggests that the down-regulation of 
muscle IGF-1 and myostatin gene expression is an early event in the course of the 
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disease. Further studies are warranted to understand whether such alterations persist or if 
a different modulation in the expression of these genes may occur in advanced disease 
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Figure 1 IGF-1 mRNA levels in the rectus abdominis muscle of gastric cancer 
patients. 
 (A) Pattern of IGF-1 expression evaluated by semi-quantitative RT-PCR. 
Upper panel: data (means ± SEM, n = 16) expressed as percentage of 
controls (C=0.46±0.14). Significance of the differences: *p<0.05 vs controls 
(n = 6). Lower panel: representative RT-PCR pattern; (B) IGF-1 expression 
evaluated by real-time PCR. Data are normalized fold expression (means ± 
SEM; controls: n = 3; patients: n = 8). Significance of the differences: *p<0.05 
vs controls. 
 
Figure 2 Myostatin mRNA levels in the rectus abdominis muscle of gastric cancer 
patients.  
 (A) Pattern of myostatin expression evaluated by semi-quantitative RT-PCR. 
Upper panel: data (means ± SEM, n = 16) expressed as percentage of 
controls (C=0.91±0.26). Significance of the differences: ***p<0.001 vs 
controls (n = 6). Lower panel: representative RT-PCR pattern. (B) Myostatin 
expression evaluated by real-time PCR. Data are normalized fold expression 
(means ± SEM; controls: n = 3; patients: n = 8). Significance of the 
differences: ***p<0.001 vs controls. 
 
Figure 3 Expression of atrogin-1 and MuRF1 in the rectus abdominis muscle of gastric 
cancer patients. 
 Upper panel: densitometric analysis. Data (means ± SEM; n = 16) expressed 
as percentage of controls (Atrogin-1: C=0.91±0.26; MuRF1: C=0.33±0.14). 
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Significance of the differences: ***p<0.001 vs controls (n = 6). Lower panel: 
representative RT-PCR pattern.  
 
Table legends 
Table 1: Characteristics  of the subjects studied. Values are expressed as means  
SEM; *p<0.05 vs. controls. 
Table 2:       Oligonucleotide sequences used for semiquantitative reverse-transcriptase 
PCR (table 1A)  and Real-time PCR (table 1B). The same oligonucleotides 
for IGF-1, Myostatin, Atrogin-1 and MuRF1 were used for both reverse 
transcriptase and Real-time PCR. The amplification protocols used for 
semiquantitative reverse-transcriptase PCR are indicated in table 1A.  
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Table 1.  
 
 Controls Patients 
Subjects  
n 6 16 
Age, years  62  5.71 64  2.75 
Type  
Adenocarcinoma (n) - 14 
Lymphoma (n) - 2 
Stage  
I-II - 12 
III-IV - 4 
Anthropometric parametrs  
Percent weight loss  0.5  0.04 5.3  1.22 
Body Mass Index  26.2  2.08 28.7  1.07 
Serum total protein (g/L) 66.7  1.84 64.8  1.4 
Serum albumin (g/L)  36.2  1.59 35.1  1 
Serum creatinine (mg/dL) 0.94  0.08 0.90  0.02 
Hemoglobin (g/dL) 14.2  0.86 11.0  0.85* 
White cell count (x103/cmm) 6.9  0.86 6.5  0.4 




Table 2.  
 
A. Reverse transcriptase-PCR 





1’   94°C 
1’   55°C 







30’’   94°C 
1’   60°C 







1’   95°C 
1’   60°C 







1’   95°C 
1’   58°C 







1’   95°C 
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B. Real-time PCR 







 FW: TGCACAGGAGCCAAGAGTGAA 
RW: CACATCACAGCTCCCCACCA 
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